All In Biotech

Drug Trial Radar · NCT03319732

A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS

An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients With Spasticity (Study OS440-3005)

Last checked: Nov 19, 2026Latest source record: Aug 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

323

Actual

Start

Apr 3, 2018

Primary completion

Jan 27, 2020

Study completion Jun 11, 2020

Sponsor

Lead sponsor
RVL Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
Osmotica Pharmaceutical US LLC
First posted
Oct 24, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Spasticity is a common complication in MS and occurs in up to 84% of patients. The main sign of spasticity is resistance to passive limb movement characterized by increased resistance to stretching, clonus, and exaggerated deep reflexes. Osmotica Pharmaceutical is currently developing arbaclofen extended-release tablets (AERT) for the treatment of spasticity in patients with MS.

Conditions

  • Multiple Sclerosis
  • Spasticity, Muscle

Interventions

  • ArbaclofenDrug

    Arbaclofen is the active R enantiomer of baclofen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events, Change in Vital Signs, Clinical Laboratory Test Results, 12-lead ECGs, USP Questionnaire, and C-SSRS ResultsTime frame: over 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Neuro Pain Medical Center

    Fresno, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.